SATT and AFRINEST Trials Released in The Lancet, Lancet Global Health

Experts from Johns Hopkins University, Save the Children’s Saving Newborn Lives, the U.S. Agency for International Development (USAID), the College of Medicine University of Ibadan, the Bill and Melinda Gates Foundation shared new evidence published in The Lancet and The Lancet Global Health with the potential to save thousands of newborn lives with low cost, effective and commonly available antibiotics.

  • Dr. Rebecca Cooney, North America Editor, Lancet
  • Katie Taylor, Deputy Assistant Administrator and Deputy Child and Maternal Health Coordinator, EPCMD, USAID
  • Joy Riggs-Perla, Senior Director, Saving Newborn Lives Program, Save the Children
  • Dr. Adejumoke Ayede, Senior Lecturer, Department of Pediatrics, College of Medicine University of Ibadan and Consultant Pediatrician, University College Hospital, Ibadan, Oyo State, Nigeria
  • Dr. Abdullah Baqui, Professor of International Health and Director of the International Center for Maternal and Newborn Health at the Johns Hopkins Bloomberg School of Public Health
  • Dr. Mariam Claeson, Director, Maternal, Newborn, and Child Health, Bill & Melinda Gates Foundation

Almost a quarter of the three million neonatal deaths annually are the result of severe infections like Sepsis – a fast progressing life-threatening illness in newborns that requires rapid treatment. Newborn sepsis can be difficult for families and even clinicians to recognize in newborns, who rapidly decline without timely and appropriate treatment. The study found that two alternative simplified regimens, which require either two or seven injections in addition to oral antibiotics given closer to home were just as effective as 14 injections in treating newborn infections. The regimens, studied in clinical settings in Africa and Asia where neonatal deaths remain stubbornly high, were found to be safe, simple and more accessible.

Read the Lancet Study

Post a Comment